Illumina Announces Initial Customer Orders for the Global Screening Array
June 16 2016 - 9:00AM
Business Wire
Universal, Whole Genome Array to Enable Wide
Breadth of Genotyping Applications for Biobanks, Disease and
Translational Research, and Consumer Genomics
Illumina, Inc. (NASDAQ: ILMN) today announced that it has signed
deals with 12 customers for its new Infinium® Global Screening
Array (GSA). In total, the company has received orders for more
than 3 million samples of the new consortia-developed array.
Initial customers include human disease researchers at The Broad
Institute and deCODE Genetics, health systems Avera Health,
Codigo46, Diagnomics, Eone Diagnomics Genome Center (EDGC), Sanford
Health and UCLA Health System, genomic service providers Centre
National de Genotypage, Human Genomics Facility HuGeF, Erasmus MC,
Life and Brain, and consumer genomics company 23andMe, Inc.
“The array content includes highly predictive hand-curated
content, as well as high value markers for translational research
applications and sample quality control (QC) designed to be useful
across a broad range of applications, populations and diseases,”
said Benjamin Neale, PhD, Assistant Professor, Analytic and
Translational Genetics Unit, Massachusetts General Hospital and The
Broad Institute, who led the predictive content selection for the
consortia.
“We were impressed that the GSA included content applicable to a
range of clinical research activities across our healthcare
ecosystem. For the moment, this is an exceptional research
opportunity,” said Dan Geschwind, MD, PhD, Gordon and Virginia
MacDonald Distinguished Professor in Neurology, Psychiatry and
Human Genetics and Senior Associate Dean and Associate Vice
Chancellor for Precision Medicine, at UCLA. “As genetics and
genomics becomes incorporated into clinical practice in the future,
we expect to be able to use these data to make the care that we
deliver in UCLA health more personalized.”
The GSA is a highly economical tool for genetic risk screening
of large global populations. With volume discounts enabling price
points below $40 per sample, it offers unparalleled genomic
coverage and imputation performance across 26 continental
populations and features approximately 50,000 hand-curated variants
relevant to clinical research, including markers for
pharmacogenomics, newborn screening research, risk profiling and
confirmation of putative clinical associations. Leveraging the
24-sample Infinium format, the array includes 660,000 markers, and
allows for the cost-effective addition of up to 50,000 custom
markers.
“The early adoption of the GSA, represented by these deals,
illustrates the widespread market demand for genotyping products
and the continued relevance of arrays in human disease and
translational research,” said Rob Brainin, Vice President and
General Manager, Applied Genomics at Illumina. “We expect that the
value of the content on this array will lead to widespread use in
clinical research, including precision medicine programs,
predictive risk screening, large scale genome-wide association
studies, and in biobank sample characterization and quality
control.”
The GSA will begin shipping in the second half of 2016. Orders
received to date occurred in the first half of 2016. For more
information, visit www.illumina.com/GlobalScreeningArray.
About Illumina, Inc.
Illumina is improving human health by unlocking the power of the
genome. Our focus on innovation has established us as the global
leader in DNA sequencing and array-based technologies, serving
customers in the research, clinical and applied markets. Our
products are used for applications in the life sciences, oncology,
reproductive health, agriculture and other emerging segments. To
learn more, visit www.illumina.com and follow @illumina.
Forward-Looking Statements
This release may contain forward-looking statements that involve
risks and uncertainties. Important factors that could cause actual
results to differ materially from those in any forward-looking
statements are detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date
of this release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160616005665/en/
Illumina, Inc.Investors:Rebecca Chambers,
858-255-5243ir@illumina.comorMedia:Gwen Gordon,
858-882-6822pr@illumina.comorEurope, Middle East and Africa:David
Robertson, +44 (0)1223 824909drobertson@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Sep 2023 to Sep 2024